Forge Biologics receives EMA PRIME designation for Krabbe disease drug

Forge Biologics has received PRIME designation from the EMA for its drug candidate FBX-101 to treat patients with Krabbe disease.

Related Keywords

,Forge Biologics Regulatory Affairs ,Infantile Krabbe ,Biologics Regulatory Affairs ,Christopher Shilling ,